Ameriprise
CSBR icon

Ameriprise’s Champions Oncology CSBR Stock Holding History

Ameriprise’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-75,044
Closed -$406K – 3867
2023
Q4 		$406K Sell
75,044
-9,043
-11% -$50.4K ﹤0.01% 3523
2023
Q3 		$523K Sell
84,087
-744
-0.9% -$4.7K ﹤0.01% 3397
2023
Q2 		$534K Buy
84,831
+4,055
+5% +$20.9K ﹤0.01% 3406
2023
Q1 		$325K Hold
80,776
– – ﹤0.01% 3589
2022
Q4 		$365K Sell
80,776
-917
-1% -$5.99K ﹤0.01% 3519
2022
Q3 		$613K Sell
81,693
-2,484
-3% -$20.8K ﹤0.01% 3311
2022
Q2 		$681K Sell
84,177
-873
-1% -$6.68K ﹤0.01% 3277
2022
Q1 		$692K Buy
85,050
+2,018
+2% +$16.2K ﹤0.01% 3356
2021
Q4 		$664K Buy
+83,032
New +$765K ﹤0.01% 3426

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ameriprise's CSBR Position: Q1 2024 in Review

Ameriprise sold out of Champions Oncology (CSBR) in Q1 2024, closing a stake of 75,044 shares — an estimated $406K sold.

Ameriprise first reported a position in CSBR in Q4 2021 and held it in 9 quarters. The position peaked at $692K in Q1 2022. 25 funds tracked by Wall St. Rank hold CSBR as of Q1 2024.

  • Ameriprise reported no remaining Champions Oncology position as of Q1 2024 after selling out during the quarter.
  • Ameriprise sold 75,044 Champions Oncology shares in Q1 2024, an estimated $406K.
  • Ameriprise first reported a position in Champions Oncology in Q4 2021 and held it in 9 quarters.
  • Ameriprise's Champions Oncology position peaked at $692K in Q1 2022.
  • 25 funds tracked by Wall St. Rank held Champions Oncology as of Q1 2024.

Based on Ameriprise's 13F filing for Q1 2024, filed 15 May 2024.